Literature DB >> 8491064

Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome.

B L Lee1, D Wong, N L Benowitz, P M Sullam.   

Abstract

Caffeine was used to assess acetylation status and indexes of oxidative drug metabolism (demethylation, xanthine oxidation, and 8-hydroxylation) in a control group and in three groups of patients infected with human immunodeficiency virus (HIV): patients with acquired immunodeficiency syndrome (AIDS) who had acute illnesses, stable patients with AIDS, and asymptomatic patients infected with HIV. The prevalence of apparent slow acetylation was greater in AIDS patients with acute illnesses compared with control subjects (27 of 29 [93%] versus 18 of 29 [62%]). Indexes of demethylation were decreased and 8-hydroxylation increased in these patients. Xanthine oxidation was the same as that in the control subjects. In the stable AIDS patients, oxidative pathways were altered in a manner similar to that observed in the AIDS patients with acute illnesses, but acetylation was the same as that in the control subjects. In HIV-infected asymptomatic patients, drug metabolism was the same as that in the control subjects. The increased prevalence of apparent slow acetylation and the altered activity of the oxidative pathways in AIDS patients with acute illnesses may partly explain the increased incidence of adverse drug reactions in these patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491064     DOI: 10.1038/clpt.1993.66

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

3.  Protein binding of clindamycin in sera of patients with AIDS.

Authors:  J F Flaherty; G Gatti; J White; J Bubp; M Borin; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.

Authors:  B L Lee; S Safrin; V Makrides; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 5.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

6.  Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity.

Authors:  D J Naisbitt; S J Hough; H J Gill; M Pirmohamed; N R Kitteringham; B K Park
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 7.  Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.

Authors:  D M Burger; P L Meenhorst; J H Beijnen
Journal:  Pharm World Sci       Date:  1995-03-24

8.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

9.  Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.

Authors:  Yat Yee Wong; Eva G Rakasz; David J Gasper; Thomas C Friedrich; Lauren A Trepanier
Journal:  Toxicology       Date:  2016-08-23       Impact factor: 4.221

10.  Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients.

Authors:  T W Chin; A Vandenbroucke; I W Fong
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.